Primary Peptides, Yabao Pharmaceutical Group deal

Primary Peptides granted Yabao exclusive rights in Taiwan and China, including Hong Kong, to develop and commercialize K13 to treat stroke. Primary Peptides will receive an upfront payment and is eli...